{"count": 4, "results": [{"_id": "20880345", "pmid": 20880345, "title": "Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.", "journal": "Diabetes Obes Metab", "authors": ["Fazio S", "Guyton JR", "Lin J", "Tomassini JE", "Shah A", "Tershakovec AM"], "date": "2010-11-01T00:00:00Z", "doi": "10.1111/j.1463-1326.2010.01289.x", "meta_date_publication": "2010 Nov", "meta_volume": "12", "meta_issue": "11", "meta_pages": "983-93", "score": 50077.668, "text_hl": "New-onset @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@DM@@@ was more frequent among @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@MetS@@@ @SPECIES_9606 @@@patients@@@ than those without @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@MetS@@@ during the first 24 weeks and trended higher among those assigned to @CHEMICAL_Nitrogen @CHEMICAL_MESH:D009584 @@@N@@@-containing regimens [n = 5(5.1%) for N, n = 2(1.7%) for @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@, n = 21(8.8%) for @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@+N]; during the 24-64 week extension study, @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ was diagnosed in five additional @SPECIES_9606 @@@patients@@@ in the @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@(cumulative incidence of 5.9%) and one in the @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@+N (cumulative incidence of 9.2%). ", "citations": {"NLM": "Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab. 2010 Nov;12(11):983-93. PMID: 20880345", "BibTeX": "@article{20880345, title={Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.}, author={Fazio S and Guyton JR and Lin J and Tomassini JE and Shah A and Tershakovec AM}, journal={Diabetes Obes Metab}, volume={12}, number={11}, pages={983-93}}"}}, {"_id": "19397693", "pmid": 19397693, "title": "Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.", "journal": "Eur J Clin Invest", "authors": ["Winkler K", "Schewe T", "Pütz G", "Odünc N", "Schäfer G", "Siegel E", "Geisen U", "Abletshauser C", "Hoffmann MM"], "date": "2009-06-01T00:00:00Z", "doi": "10.1111/j.1365-2362.2009.02126.x", "meta_date_publication": "2009 Jun", "meta_volume": "39", "meta_issue": "6", "meta_pages": "463-70", "score": 50070.863, "text_hl": "@CHEMICAL_Fluvastatin @CHEMICAL_MESH:D000077340 @@@Fluvastatin@@@/@CHEMICAL_Fenofibrate @CHEMICAL_MESH:D011345 @@@fenofibrate@@@ vs. @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@: different effects on LDL-profiles.", "citations": {"NLM": "Winkler K, Schewe T, Pütz G, Odünc N, Schäfer G, Siegel E, Geisen U, Abletshauser C, Hoffmann MM. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009 Jun;39(6):463-70. PMID: 19397693", "BibTeX": "@article{19397693, title={Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.}, author={Winkler K and Schewe T and Pütz G and Odünc N and Schäfer G and Siegel E and Geisen U and Abletshauser C and Hoffmann MM}, journal={Eur J Clin Invest}, volume={39}, number={6}, pages={463-70}}"}}, {"_id": "21291725", "pmid": 21291725, "title": "Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses.", "journal": "J Clin Lipidol", "authors": ["Abate N", "Catapano AL", "Ballantyne CM", "Davidson MH", "Polis A", "Smugar SS", "Tershakovec AM"], "date": "2008-04-01T00:00:00Z", "doi": "10.1016/j.jacl.2008.02.002", "meta_date_publication": "2008 Apr", "meta_volume": "2", "meta_issue": "2", "meta_pages": "91-105", "score": 50069.547, "text_hl": "CONCLUSIONS: Overall, @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ generally provided greater efficacy than either @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ or @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ that was consistent across the subgroups of @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@DM@@@, @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@MS@@@, or neither, in agreement with the results from the full study cohorts.", "citations": {"NLM": "Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, Tershakovec AM. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. J Clin Lipidol. 2008 Apr;2(2):91-105. PMID: 21291725", "BibTeX": "@article{21291725, title={Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses.}, author={Abate N and Catapano AL and Ballantyne CM and Davidson MH and Polis A and Smugar SS and Tershakovec AM}, journal={J Clin Lipidol}, volume={2}, number={2}, pages={91-105}}"}}, {"_id": "28437620", "pmid": 28437620, "title": "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.", "journal": "Endocr Pract", "authors": ["Jellinger PS", "Handelsman Y", "Rosenblit PD", "Bloomgarden ZT", "Fonseca VA", "Garber AJ", "Grunberger G", "Guerin CK", "Bell DSH", "Mechanick JI", "Pessah-Pollack R", "Wyne K", "Smith D", "Brinton EA", "Fazio S", "Davidson M"], "date": "2017-04-01T00:00:00Z", "doi": "10.4158/EP171764.APPGL", "meta_date_publication": "2017 Apr", "meta_volume": "23", "meta_issue": "Suppl 2", "meta_pages": "1-87", "score": 50024.215, "text_hl": "ABBREVIATIONS: 4S = Scandinavian @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Survival Study @VARIANT_c.1A>C_SPTB_human @VARIANT_tmVar:c|SUB|A|1|C;HGVS:c.1A>C;VariantGroup:0;CorrespondingGene:6710;CorrespondingSpecies:9606 @@@A1C@@@ = glycated hemoglobin AACE = American Association of Clinical Endocrinologists AAP = American Academy of Pediatrics ACC = American College of Cardiology ACE = American College of Endocrinology ACS = @DISEASE_Acute_Coronary_Syndrome @DISEASE_MESH:D054058 @@@acute coronary syndrome@@@ ADMIT = @DISEASE_Cerebral_Arterial_Diseases @DISEASE_MESH:D002539 @@@Arterial Disease@@@ Multiple Intervention Trial ADVENT = Assessment of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Control and Evaluation of the Efficacy of Niaspan Trial AFCAPS/TexCAPS = Air Force/Texas @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@Coronary Atherosclerosis@@@ Prevention Study AHA = American Heart Association AHRQ = Agency for Healthcare Research and Quality AIM-HIGH = Atherothrombosis Intervention in @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@Metabolic Syndrome@@@ With Low HDL/High @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@Triglycerides@@@ trial ASCVD = @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherosclerotic cardiovascular disease@@@ ATP = Adult Treatment Panel apo = apolipoprotein BEL = best evidence level BIP = @CHEMICAL_Bezafibrate @CHEMICAL_MESH:D001629 @@@Bezafibrate@@@ Infarction Prevention trial BMI = body mass index CABG = coronary artery bypass graft CAC = @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@coronary artery calcification@@@ CARDS = Collaborative @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@Atorvastatin@@@ @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Study CDP = Coronary Drug Project trial CI = confidence interval CIMT = carotid intimal media thickness @DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder @DISEASE_MESH:D012080 @@@CKD@@@ = @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@chronic kidney disease@@@ CPG(s) = clinical practice guideline(s) CRP = @GENE_CRP @GENE_1401 @@@C-reactive protein@@@ CTT = @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Treatment Trialists CV = cerebrovascular CVA = cerebrovascular accident EL = evidence level FH = @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ FIELD = Secondary Endpoints from the Fenofibrate Intervention and Event Lowering in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ trial FOURIER = Further Cardiovascular Outcomes Research with @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ Inhibition in Subjects With Elevated Risk trial HATS = HDL-@DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ Treatment Study HDL-C = high-density lipoprotein @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@ HeFH = heterozygous @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ HHS = Helsinki Heart Study @SPECIES_11676 @@@HIV@@@ = @SPECIES_12721 @@@human immunodeficiency virus@@@ HoFH = homozygous @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@familial hypercholesterolemia@@@ HPS = Heart Protection Study HPS2-THRIVE = Treatment of HDL to Reduce the Incidence of Vascular Events trial HR = hazard ratio HRT = hormone replacement therapy hsCRP = high-sensitivity CRP IMPROVE-IT = Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial IRAS = @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@Insulin Resistance Atherosclerosis@@@ Study JUPITER = Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@Rosuvastatin@@@ LDL-C = low-density lipoprotein cholesterol Lp-PLA2 = lipoprotein-associated phospholipase A2 MACE = major cardiovascular events MESA = Multi-Ethnic Study of @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ MetS = @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@ MI = @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@ MRFIT = Multiple Risk Factor Intervention Trial NCEP = National @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Education Program NHLBI = National Heart, Lung, and Blood Institute @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@ = @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@polycystic ovary syndrome@@@ @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ = @GENE_PCSK9 @GENE_255738 @@@proprotein convertase subtilisin/kexin type 9@@@ Post CABG = Post Coronary Artery Bypass Graft trial PROSPER = Prospective Study of @CHEMICAL_Pravastatin @CHEMICAL_MESH:D017035 @@@Pravastatin@@@ in the Elderly at Risk trial QALY = quality-adjusted life-year ROC = receiver-operator characteristic SOC = standard of care SHARP = Study of Heart and Renal Protection T1DM = type 1 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ mellitus T2DM = type 2 @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ mellitus TG = @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@triglycerides@@@ TNT = Treating to New Targets trial VA-HIT = Veterans Affairs High-Density Lipoprotein @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Intervention Trial VLDL-C = very low-density lipoprotein cholesterol WHI = @SPECIES_9606 @@@Women@@@'s Health Initiative.", "citations": {"NLM": "Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. PMID: 28437620", "BibTeX": "@article{28437620, title={AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.}, author={Jellinger PS and Handelsman Y and Rosenblit PD and Bloomgarden ZT and Fonseca VA and Garber AJ and Grunberger G and Guerin CK and Bell DSH and Mechanick JI and Pessah-Pollack R and Wyne K and Smith D and Brinton EA and Fazio S and Davidson M}, journal={Endocr Pract}, volume={23}, number={Suppl 2}, pages={1-87}}"}}]}